| Identification | Back Directory | [Name]
OSI-754 | [CAS]
1190094-64-4 | [Synonyms]
LNK 754 OSI-754 CP 609754 CP-609754(OS1754) CP-609754 (OSI754) CP-609754 (OSI754, LNK 754) 6-[(R)-(4-chlorophenyl)-hydroxy-(3-methylimidazol-4-yl)methyl]-4-(3-ethynylphenyl)-1-methylquinolin-2-one 2(1H)-Quinolinone, 6-[(R)-(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl- Malignant,farnesylation,Farnesyltransferase,Tumor,Inhibitor,LNK-754,CP-609754,H-Ras,Ftase,OSI 754,Farnesyl Transferase,LNK 754,OSI-754,inhibit,OSI754,CP 609754,LNK754,K-Ras,Advanced,CP609754 | [Molecular Formula]
C29H22ClN3O2 | [MOL File]
1190094-64-4.mol | [Molecular Weight]
479.96 |
| Chemical Properties | Back Directory | [Boiling point ]
702.4±60.0 °C(Predicted) | [density ]
1.23±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (208.35 mM; Need ultrasonic) | [form ]
Solid | [pka]
12.28±0.29(Predicted) | [color ]
Off-white to yellow | [InChI]
InChI=1/C29H22ClN3O2/c1-4-19-6-5-7-20(14-19)24-16-28(34)33(3)26-13-10-22(15-25(24)26)29(35,27-17-31-18-32(27)2)21-8-11-23(30)12-9-21/h1,5-18,35H,2-3H3/t29-/s3 | [InChIKey]
JAHDAIPFBPPQHQ-NNFJEGBSNA-N | [SMILES]
N1(C)C2=C(C=C([C@@](C3=CC=C(Cl)C=C3)(O)C3N(C)C=NC=3)C=C2)C(C2=CC=CC(C#C)=C2)=CC1=O |&1:6,r| |
| Hazard Information | Back Directory | [Uses]
CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC50 for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL[1]. CP-609754 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [in vivo]
CP-609754 (CP-609,754) has antitumor activity against 3T3 H-ras (61L) tumors in vivo[1].
With twice daily oral dosing of CP-609754, tumor regression is achieved with a dose of 100 mg/kg; the ED50 for tumor growth inhibition is 28 mg/kg[1].
With continuous i.p. infusion of CP-609754, tumor growth is inhibited by >50%, and tumor farnesyltransferase activity inhibited by >30% in mice in which the plasma concentration of CP-609754 is maintained above 118 ng/mL[1]. | [References]
[1] Stacy L Moulder, et al. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004 Nov 1;10(21):7127-35. DOI:10.1158/1078-0432.CCR-04-0901 |
|
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Twochem Co.Ltd.
|
| Telephone: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
| Company Name: |
InvivoChem
|
| Telephone: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|